Related Experiment Video
Updated: Jul 17, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Clinical pharmacology education: looking into the future
J D Gray1, D Danoff, A M Shepherd
1Dalhousie University, Halifax, Nova Scotia, Canada. jeangray@eastlink.ca
Clinical Pharmacology and Therapeutics
|January 30, 2007
Summary
The number of clinical pharmacology specialists is decreasing, prompting a review of training programs. Discussion is needed to ensure future needs in drug development and policy are met.
Area of Science:
- Pharmacology
- Medical Education
- Healthcare Workforce Analysis
Background:
- The practice of clinical pharmacology is experiencing a decline in specialist numbers.
- This trend raises critical questions regarding the discipline's scope and the evolving roles of its practitioners.
- Addressing this decline is crucial for maintaining expertise in drug-related fields.
Purpose of the Study:
- To present data on the numbers and qualifications of trainees in North American accredited clinical pharmacology programs.
- To stimulate a discussion among experts on the future of clinical pharmacology training.
- To ensure training programs align with future healthcare, drug development, and policy requirements.
Main Methods:
- Analysis of trainee data from accredited North American clinical pharmacology programs.
- Identification of trends in specialist numbers and qualifications.
- Formulation of discussion points for a multi-stakeholder forum.
Main Results:
- Data on successful trainees in clinical pharmacology programs are presented.
- The study highlights a declining trend in practicing clinical pharmacologists.
- Key questions are posed for future discussion and strategic planning.
Conclusions:
- The decline in clinical pharmacologists necessitates a re-evaluation of training strategies.
- A collaborative discussion involving academic, regulatory, and industry scientists is essential.
- Future training must adapt to meet the evolving needs of clinical care, drug development, and drug policy.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...